Extrawell Pharma (00858) announced that the group is expected to incur a loss of approximately HKD 160 million to HKD 165 million...
Extrawell Pharma (00858) announced that the group is expected to incur a loss of approximately HKD 160 million to HKD 165 million, compared to a profit for the fiscal year ended March 31, 2023.
The announcement stated that the loss-to-profit reversal was primarily due to non-cash items, resulting from the fair value changes of financial assets (i.e. convertible bonds investments) recognized in profit or loss, while the same non-cash item in the corresponding period last year recognized fair value changes of gain.